Blood eosinophil levels as a biomarker in COPD

Respiratory Medicine

Volumn 138, Issue , 2018, Pages 21-31

  Brusselle, Guy ^a   Pavord, Ian D ^b   Landis, Sarah ^c   Pascoe, Steven ^c   Lettis, Sally ^c   Morjaria, Nikhil ^d   Barnes, Neil ^c   Hilton, Emma ^c  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

COPD; Corticosteroids; Eosinophils; Exacerbations

Indexed keywords

ANTIBIOTIC AGENT; BECLOMETASONE DIPROPIONATE; BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE; BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE; BENRALIZUMAB; BIOLOGICAL MARKER; BRONCHODILATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL FUMARATE; GLYCOPYRRONIUM; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; MEPOLIZUMAB; PLACEBO; PREDNISOLONE; TIOTROPIUM BROMIDE; UMECLIDINIUM PLUS VILANTEROL; VILANTEROL; GLUCOCORTICOID;

ALLERGIC ASTHMA; ANTIBIOTIC THERAPY; ASTHMA; BLOOD CELL COUNT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; EOSINOPHIL; EOSINOPHIL COUNT; EOSINOPHILIA; HUMAN; MEDICAL HISTORY; MEDLINE; OBSERVATIONAL STUDY; PHENOTYPE; POST HOC ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RESPIRATORY TRACT INFLAMMATION; REVIEW; RISK FACTOR; SPUTUM; SYSTEMATIC REVIEW; TREATMENT RESPONSE; BLOOD; LEUKOCYTE COUNT; PATHOLOGY; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

BIOMARKERS; DISEASE PROGRESSION; EOSINOPHILS; GLUCOCORTICOIDS; HUMANS; LEUKOCYTE COUNT; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 85044463622     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2018.03.016     Document Type: Review

References (77)

1. World Health Organization, The 10 Leading Causes of Death in the World in 2015. 2017 [updated January 2017]. Available from http://www.who.int/mediacentre/factsheets/fs310/en/.
2. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2017 Available from http://goldcopd.org.
3. Matera, M.G., Cardaci, V., Cazzola, M., Rogliani, P., Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. Expert Opin. Drug Saf. 14:4 (2015), 533–541, 10.1517/14740338.2015.1001363.
4. Brightling, C.E., Biomarkers that predict and guide therapy for exacerbations of chronic obstructive pulmonary disease. Ann. Am. Thorac. Soc., 10(Suppl:S214–9), 2013.
5. Balbi, B., Aufiero, A., Pesci, A., Oddera, S., Zanon, P., Rossi, G.A., et al. Lower respiratory tract inflammation in chronic bronchitis. Evaluation by bronchoalveolar lavage and changes associated with treatment with Immucytal, a biological response modifier. Chest 106:3 (1994), 819–826.
6. Keatings, V.M., Barnes, P.J., Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am. J. Respir. Crit. Care Med. 155:2 (1997), 449–453.
7. Papi, A., Romagnoli, M., Baraldo, S., Braccioni, F., Guzzinati, I., Saetta, M., et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 162:5 (2000), 1773–1777.
8. Bathoorn, E., Kerstjens, H., Postma, D., Timens, W., MacNee, W., Airways inflammation and treatment during acute exacerbations of COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 3:2 (2008), 217–229.
9. Gao, P., Zhang, J., He, X., Hao, Y., Wang, K., Gibson, P.G., Sputum inflammatory cell-based classification of patients with acute exacerbation of chronic obstructive pulmonary disease. PLoS One, 8(5), 2013, e57678.
10. Saetta, M., Di Stefano, A., Maestrelli, P., Turato, G., Ruggieri, M.P., Roggeri, A., et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am. J. Respir. Crit. Care Med. 150:6 Pt 1 (1994), 1646–1652.
11. Fujimoto, K., Yasuo, M., Urushibata, K., Hanaoka, M., Koizumi, T., Kubo, K., Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. Eur. Respir. J. 25:4 (2005), 640–646.
12. Vedel-Krogh, S., Nielsen, S.F., Lange, P., Vestbo, J., Nordestgaard, B.G., Blood eosinophils and exacerbations in COPD: the Copenhagen General Population Study. Am. J. Respir. Crit. Care Med. 193:9 (2016), 965–974.
13. Trevor, J.L., Deshane, J.S., Refractory asthma: mechanisms, targets, and therapy. Allergy 69:7 (2014), 817–827, 10.1111/all.12412.
14. Kerkhof, M., Freeman, D., Jones, R., Chisholm, A., Price, D.B., Respiratory Effectiveness Group. Predicting frequent COPD exacerbations using primary care data. Int. J. Chron. Obstruct. Pulmon. Dis. 10 (2015), 2439–2450.
15. Singh, D., Kolsum, U., Brightling, C.E., Locantore, N., Agusti, A., Tal-Singer, R., et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur. Respir. J. 44:6 (2014), 1697–1700.
16. Weir, M., Zhao, H., Han, M.K., Kanner, R., Pirozzi, C.S., Scholand, M.B., et al. Eosinophils in chronic obstructive pulmonary disease, the SPIROMICS cohort. Am. J. Respir. Crit. Care Med., 189, 2014 A5902.
17. Pascoe, S., Locantore, N., Dransfield, M.T., Barnes, N.C., Pavord, I.D., Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir. Med. 3:6 (2015), 435–442.
18. Vestbo, J., Papi, A., Corradi, M., Blazhko, V., Montagna, I., Francisco, C., et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet 389:10082 (2017), 1919–1929, 10.1016/S0140-6736(17)30188-5.
19. Cheng, S.L., Lin, C.H., Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts. Int. J. Chron. Obstruct. Pulmon. Dis. 11 (2016), 2341–2348.
20. Pavord, I.D., Lettis, S., Locantore, N., Pascoe, S., Jones, P.W., Wedzicha, J.A., et al. Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. Thorax 71:2 (2016), 118–125.
21. Suzuki, M., Makita, H., Konno, S., Nishimura, M., Association of differential white blood cell counts with clinical course of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 191, 2015 A2929.
22. Siddiqui, S.H., Guasconi, A., Vestbo, J., Jones, P., Agusti, A., Paggiaro, P., et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 192:4 (2015), 523–525.
23. Barnes, N.C., Sharma, R., Lettis, S., Calverley, P.M., Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur. Respir. J. 47:5 (2016), 1374–1382.
24. Bafadhel, M., Davies, L., Calverley, P.M., Aaron, S.D., Brightling, C.E., Pavord, I.D., Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur. Respir. J. 44:3 (2014), 789–791.
25. Serafino-Agrusa, L., Scichilone, N., Spatafora, M., Battaglia, S., Blood eosinophils and treatment response in hospitalized exacerbations of chronic obstructive pulmonary disease: a case-control study. Pulm. Pharmacol. Ther. 37 (2016), 89–94.
26. Donaldson, G.C., Mackay, A.J., Whitmore, G.A., Aaron, S.D., Wedzicha, J.A., Stable blood eosinophil percentage predicts exacerbation recovery in COPD. Am. J. Respir. Crit. Care Med., 191, 2015 A2920.
27. Russell, R.E.K., Doggett, T., Pavord, I., Pullinger, R., Beer, S., Bafadhel, M., COPD in the ED: eosinophils, treatment and outcomes, data from the pre-award study. Thorax 71 (2016), A40–A41.
28. Pizzichini, E., Pizzichini, M.M., Gibson, P., Parameswaran, K., Gleich, G.J., Berman, L., et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am. J. Respir. Crit. Care Med. 158:5 Pt 1 (1998), 1511–1517.
29. Bafadhel, M., Greening, N.J., Harvey-Dunstan, T.C., Williams, J.E., Morgan, M.D., Brightling, C.E., et al. Blood eosinophils and outcomes in severe hospitalised exacerbations of COPD. Chest 150:2 (2016), 320–328.
30. Siva, R., Green, R.H., Brightling, C.E., Shelley, M., Hargadon, B., McKenna, S., et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur. Respir. J. 29:5 (2007), 906–913.
31. Watz, H., Tetzlaff, K., Wouters, E.F., Kirsten, A., Magnussen, H., Rodriguez-Roisin, R., et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir. Med. 4:5 (2016), 390–398.
32. Roche, N., Chapman, K.R., Vogelmeier, C.F., Herth, F.J.F., Thach, C., Fogel, R., et al. Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. Data from the FLAME Trial. Am. J. Respir. Crit. Care Med. 195:9 (2017), 1189–1197, 10.1164/rccm.201701-0193OC.
33. Wedzicha, J.A., Price, D.B., Mezzi, K., Fogel, R., Banjeri, D., QVA149 compared with salmeterol/fluticasone (SFC) on exacerbations and its correlation with baseline blood eosinophils: a pooled analysis of LANTERN and ILLUMINATE. Eur. Respir. J., 46(Suppl 59), 2015 PA1005.
34. Scott, K.A., Wardlaw, A.J., Eosinophilic airway disorders. Semin. Respir. Crit. Care Med. 27:2 (2006), 128–133.
35. Diny, N.L., Rose, N.R., Čiháková D., Eosinophils in autoimmune diseases. Front. Immunol., 8, 2017, 484, 10.3389/fimmu.2017.00484.
36. Eltboli, O., Brightling, C.E., Eosinophils as diagnostic tools in chronic lung disease. Expert Rev. Respir. Med. 7:1 (2013), 33–42.
37. Zhu, J., Qiu, Y.S., Majumdar, S., Gamble, E., Matin, D., Turato, G., et al. Exacerbations of bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am. J. Respir. Crit. Care Med. 164:1 (2001), 109–116.
38. Taylor, R.G., Gross, E., Joyce, H., Holland, F., Pride, N.B., Smoking, allergy, and the differential white blood cell count. Thorax 40:1 (1985), 17–22.
39. Belda, J., Leigh, R., Parameswaran, K., O'Byrne, P.M., Sears, M.R., Hargreave, F.E., Induced sputum cell counts in healthy adults. Am. J. Respir. Crit. Care Med. 161:2 Pt 1 (2000), 475–478.
40. Bafadhel, M., McKenna, S., Terry, S., Mistry, V., Reid, C., Haldar, P., et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am. J. Respir. Crit. Care Med. 184:6 (2011), 662–671.
41. Hastie, A.T., Alexis, N.E., Doerschuk, C., Hansel, N.N., Christenson, S., Putcha, N., et al. Blood eosinophils poorly correlate with sputum eosinophils, and have few associations with spirometry, clinical and quantitated computed tomography measures compared to sputum eosinophils in the SPIROMICS cohort. Am. J. Respir. Crit. Care Med., 193, 2016 A6168.
42. Landis, S., Suruki, R., Bonar, K., Hilton, E., Compton, C., Blood eosinophil levels in COPD patients in the UK Clinical Practice Research Datalink (CPRD). Am. J. Respir. Crit. Care Med., 193, 2016 A6329.
43. DiSantostefano, R.L., Hinds, D., Le, H.V., Barnes, N.C., Relationship between blood eosinophils and clinical characteristics in a cross-sectional study of a US population-based COPD cohort. Respir. Med. 112 (2016), 88–96.
44. Hardin, M., Putcha, N., Hansel, N.N., Ramsdell, J.W., Van Beek, E., Hanania, N.A., et al. The significance of peripheral blood eosinophils and IgE levels in COPDGene subjects. Am. J. Respir. Crit. Care Med., 191, 2015 A2921.
45. Eltboli, O., Bafadhel, M., Hollins, F., Wright, A., Hargadon, B., Kulkarni, N., et al. COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils. BMC Pulm. Med., 14, 2014, 112.
46. D'Armiento, J.M., Scharf, S.M., Roth, M.D., Connett, J.E., Ghio, A., Sternberg, D., et al. Eosinophil and T cell markers predict functional decline in COPD patients. Respir. Res., 10, 2009, 113.
47. Hurst, J.R., Vestbo, J., Anzueto, A., Locantore, N., Mullerova, H., Tal-Singer, R., et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 363:12 (2010), 1128–1138.
48. Bacci, E., Cianchetti, S., Bartoli, M., Dente, F.L., Di Franco, A., Vagaggini, B., et al. Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients. Chest 129:3 (2006), 565–572.
49. Bafadhel, M., McKenna, S., Terry, S., Mistry, V., Pancholi, M., Venge, P., et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am. J. Respir. Crit. Care Med. 186:1 (2012), 48–55, 10.1164/rccm.201108-1553OC.
50. Wedzicha, J.A., Banerji, D., Chapman, K.R., Vestbo, J., Roche, N., Ayers, R.T., et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N. Engl. J. Med. 374:23 (2016), 2222–2234.
51. Siddiqui, S.H., Pavord, I., Barnes, N.C., Lettis, S., Guasconi, A., Petruzzelli, S., LATE-BREAKING ABSTRACT: Blood eosinophils (EOS) are a biomarker of COPD exacerbation reduction with inhaled corticosteroids (ICS): an across-trials model-based approach. Eur. Respir. J., 48, 2016 OA1763.
52. Kreindler, J., Locantore, N., Watkins, M., Lettis, S., Tal-Singer, R., Minimal effect of inhaled corticosteroids (ICS) on blood eosinophil count in steroid-naïve COPD patients. Eur. Respir. J., 46(Suppl 59), 2015 PA2959.
53. Barnes, N.C., Qiu, Y.S., Pavord, I.D., Parker, D., Davis, P.A., Zhu, J., et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 173:7 (2006), 736–743.
54. Bourbeau, J., Christodoulopoulos, P., Maltais, F., Yamauchi, Y., Olivenstein, R., Hamid, Q., Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 62:11 (2007), 938–943.
55. Gibson, P., McDonald, V., Asthma-COPD overlap 2015: now we are six. Thorax 70:7 (2015), 683–691.
56. Evans, P.M., O'Connor, B.J., Fuller, R.W., Barnes, P.J., Chung, K.F., Effect of inhaled corticosteroids on peripheral blood eosinophil counts and density profiles in asthma. J. Allergy Clin. Immunol. 91:2 (1993), 643–650.
57. Kitaguchi, Y., Komatsu, Y., Fujimoto, K., Hanaoka, M., Kubo, K., Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int. J. Chron. Obstruct. Pulmon. Dis. 7 (2012), 283–289.
58. Iqbal, A., Barnes, N.C., Brooks, B., Is blood eosinophil count a predictor of response to bronchodilators in COPD?. Eur. Respir. J., 44(Suppl 58), 2014 P2819.
59. Calverley, P., Hallmann, C., Metzdorf, N., Grnke, L., Mueller, A., Halpin, D., LATE-BREAKING ABSTRACT: Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels. Eur. Respir. J., 46(Suppl 59), 2015 PA4362.
60. Leckie, M.J., ten Brinke, A., Khan, J., Diamant, Z., O'Connor, B.J., Walls, C.M., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356:9248 (2000), 2144–2148.
61. Ortega, H.G., Liu, M.C., Pavord, I.D., Brusselle, G.G., FitzGerald, J.M., Chetta, A., et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 371:13 (2014), 1198–1207.
62. Pavord, I.D., Korn, S., Howarth, P., Bleecker, E.R., Buhl, R., Keene, O.N., et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380:9842 (2012), 651–659.
63. Saetta, M., Di Stefano, A., Maestrelli, P., Turato, G., Mapp, C.E., Pieno, M., et al. Airway eosinophilia and expression of interleukin-5 protein in asthma and in exacerbations of chronic bronchitis. Clin. Exp. Allergy 26:7 (1996), 766–774.
64. Bafadhel, M., McCormick, M., Saha, S., McKenna, S., Shelley, M., Hargadon, B., et al. Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease. Respiration 83:1 (2012), 36–44.
65. Brightling, C.E., Bleecker, E.R., Panettieri, R.A. Jr., Bafadhel, M., She, D., Ward, C.K., et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir. Med. 2:11 (2014), 891–901.
66. Haldar, P., Brightling, C.E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 360:10 (2009), 973–984.
67. Szefler, S.J., Wenzel, S., Brown, R., Erzurum, S.C., Fahy, J.V., Hamilton, R.G., et al. Asthma outcomes: biomarkers. J. Allergy Clin. Immunol. 129:3 Suppl (2012), S9–S23.
68. Winkel, P., Statland, B.E., Saunders, A.M., Osborn, H., Kupperman, H., Within-day physiologic variation of leukocyte types in healthy subjects as assayed by two automated leukocyte differential analyzers. Am. J. Clin. Pathol. 75:5 (1981), 693–700.
69. Mensinga, T.T., Schouten, J.P., Weiss, S.T., Van der Lende, R., Relationship of skin test reactivity and eosinophilia to level of pulmonary function in a community-based population study. Am. Rev. Respir. Dis. 146:3 (1992), 638–643.
70. Bain, B., Seed, M., Godsland, I., Normal values for peripheral blood white cell counts in women of four different ethnic origins. J. Clin. Pathol. 37:2 (1984), 188–193.
71. Landis, S.H., Suruki, R., Galwey, N.W., Stability of blood eosinophil count in COPD patients in the UK Clinical Practice Research Datalink. Eur. Respir. J., 46, 2015 PA4047.
72. Negewo, N.A., McDonald, V.M., Baines, K.J., Wark, P.A., Simpson, J.L., Jones, P.W., et al. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 11 (2016), 1495–1504.
73. Shekelle, R.B., Shryock, A.M., Paul, O., Lepper, M., Stamler, J., Liu, S., et al. Diet, serum cholesterol, and death from coronary heart disease. The Western Electric study. N. Engl. J. Med. 304:2 (1981), 65–70.
74. Amur, S., LaVange, L., Zineh, I., Buckman-Garner, S., Woodcock, J., Biomarker qualification: toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization. Clin. Pharmacol. Ther. 98:1 (2015), 34–46.
75. Miller, B.E., Tal-Singer, R., Rennard, S.I., Furtwaengler, A., Leidy, N., Lowings, M., et al. Plasma fibrinogen qualification as a drug development tool in chronic obstructive pulmonary disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium. Am. J. Respir. Crit. Care Med. 193:6 (2016), 607–613.
76. Kolsum, U., Donaldson, G.C., Singh, R., Barker, B.L., Gupta, V., George, L., et al. Blood and sputum eosinophils in COPD; relationship with bacterial load. Respir. Res., 18(1), 2017, 88.
77. Papi, A., Bellettato, C.M., Braccioni, F., Romagnoli, M., Casolari, P., Caramori, G., et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 173:10 (2006), 1114–1121.